<! –

->

November 8, 2018 – By Vivian Park

Analysts expect MediWound Ltd. (NASDAQ: MDWD) publishes EPS of -0.19 USD on 15 November. They expect EPS of US $ 0.03, or 18.75% on EPS of -0.16 last quarter. After having already presented a BPA of -0.15 $, the badysts of MediWound Ltd. see EPS growth of 26.67%. The stock decreased by 0.17% or $ 0.01 during the last trading session to reach $ 5.79. About 31,842 shares traded, 17.18% above average. MediWound Ltd. (NASDAQ: MDWD) has increased 13.04% since November 8, 2017 and is on the rise. It underperformed the S & P500 by 2.58%.

Coverage of MediWound Ltd. Reviews (NASDAQ: MDWD)

Of the 2 badysts covering Mediwound (NASDAQ: MDWD), 2 have a purchase rating, 0 a sale and 0 an outfit. So 100% are positive. Mediwound had 3 badyst reports since May 10, 2018 according to SRatingsIntel. The action "MediWound Ltd." (NASDAQ: MDWD) was awarded the "Purchase" rating of Thursday, May 10 by Oppenheimer. Oppenheimer maintained it with a "buy" rating and a goal of $ 1,400 in the report on Monday, June 11th.

MediWound Ltd., an integrated biopharmaceutical company, focuses on the development, manufacture and commercialization of new therapeutic products in Israel. The company has a market capitalization of $ 157.37 million. It markets NexoBrid, a biopharmaceutical product intended for the elimination of pressure sore, a dead or damaged tissue in adults suffering from deep thermal burns, of partial or total thickness. He currently has negative gains. The company is also developing EscharEx, which is currently undergoing Phase II clinical trials for the debridement of chronic wounds and other wounds difficult to heal.

Another important and important news from MediWound Ltd. (NASDAQ: MDWD) was published by Nasdaq.com. She published an article titled: "MediWound will host the third quarter 2018 financial results conference call on November 13 at 8:30 am ET, November 07, 2018.

By Vivian Park